| View printer-friendly version|
|Exicure to Present at Spring Investor Summit 2019|
SKOKIE, Ill.--(BUSINESS WIRE)--Mar. 26, 2019--
Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
constructs, announced today that its CFO, David Snyder, will give a
company presentation on Tuesday, April 2, 2019 at 9:30 am ET at the
Spring Investor Summit. The presentation will be made at the Essex House
in New York City.
A live audio webcast will be available on the Investors section of
Exicure’s website: www.exicuretx.com.
The webcast will be archived for approximately 30 days following the
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company developing
therapeutics for immuno-oncology, inflammatory diseases and genetic
disorders based on our proprietary Spherical Nucleic Acid, or SNA
technology. We believe Exicure's proprietary SNA architecture has
distinct chemical and biological properties that may provide advantages
over other nucleic acid therapeutics and may have therapeutic potential
to target diseases not typically addressed with other nucleic acid
therapeutics. Exicure's lead program is in a Phase1b/2 trial in patients
with advanced solid tumors. Exicure is based outside of Chicago, IL. www.exicuretx.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190326005224/en/
Source: Exicure, Inc.